Rush Street Interactive Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Rush Street Interactive Inc trades at $33.46 (market cap $3.55B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 34.4× Rush Street Interactive Inc's market cap, and Rush Street Interactive Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| RSI | VRTX | |
|---|---|---|
Market Cap | $3.55B | $121.95B |
Sector | Technology | Health |
52-Week High | $34.52 | $529.59 |
52-Week Low | $14.55 | $366.54 |
Enterprise Value | $3.23B | $116.69B |
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $34.52, up 6.22% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 EPS of $0.14, beating expectations, and maintains strong revenue growth projections for 2026. Recent expansion into Alberta and positive analyst coverage highlight operational momentum amid a high valuation multiple.
Outlook remains positive with 77% analyst buy ratings and a consensus price target of $30.44, though the stock trades above target. Risks include elevated P/E of 95.59 and net margin pressure at 2.98%. Earnings on July 29, 2026, will be critical for validating growth trajectory amid competitive and regulatory headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →